This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Scotiabank Sticks to Its Buy Rating for Gilead Sciences (GILD)

Tipranks - Tipranks - Thu Jun 4, 7:56AM CDT

Scotiabank analyst Louise Chen maintained a Buy rating on Gilead Sciences today and set a price target of $177.00.

Claim 55% Off TipRanks

Chen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Bristol-Myers Squibb. According to TipRanks, Chen has an average return of 3.0% and a 45.45% success rate on recommended stocks.

In addition to Scotiabank, Gilead Sciences also received a Buy from Truist Financial’s Gregory Renza in a report issued today. However, on June 1, RBC Capital maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).

See Insiders’ Hot Stocks on TipRanks >>

Based on Gilead Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.96 billion and a net profit of $2.02 billion. In comparison, last year the company earned a revenue of $6.67 billion and had a net profit of $1.32 billion

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).